|
During exposure to bDMARDs/JAKIs with or without methotrexate, %
|
|
TNF inhibitors
|
67.3
|
56.6
|
51.0
|
< 0.001
|
|
Infliximab
|
12.6
|
6.1
|
2.6
|
< 0.001
|
|
Etanercept
|
20.6
|
18.0
|
17.2
|
0.001
|
|
Adalimumab
|
18.8
|
10.1
|
6.3
|
< 0.001
|
|
Golimumab
|
15.4
|
22.3
|
25.5
|
< 0.001
|
|
Certolizumab pegol
|
6.8
|
4.9
|
2.9
|
< 0.001
|
|
Tocilizumab
|
28.0
|
24.9
|
21.0
|
< 0.001
|
|
Abatacept
|
14.4
|
27.8
|
38.4
|
< 0.001
|
|
JAKIs
|
6.0
|
7.5
|
7.0
|
0.034
|
|
Tofacitinib
|
3.7
|
4.6
|
4.4
|
0.143
|
|
Baricitinib
|
2.3
|
3.1
|
2.9
|
0.140
|
|
Methotrexate or any immunosuppressive DMARD use
|
71.6
|
67.4
|
54.7
|
< 0.001
|
|
Methotrexate
|
63.0
|
52.9
|
37.7
|
< 0.001
|
|
Taclolimus
|
14.4
|
18.5
|
19.3
|
< 0.001
|
|
Mizoribine
|
2.3
|
3.6
|
3.8
|
< 0.001
|
|
Leflunomide
|
1.4
|
1.6
|
1.0
|
0.157
|
|
Oral CS use, %
|
52.4
|
57.4
|
66.2
|
< 0.001
|
|
Maximum dose of oral CS c≥ 10 mg/day, %
|
19.5
|
18.6
|
21.7
|
0.017
|
|
Mean dose of oral CS c≥ 10 mg/day, %
|
8.8
|
7.7
|
10.3
|
0.001
|
|
Mean dose of oral CS c≥ 7.5 mg/day, %
|
11.6
|
12.0
|
15.5
|
< 0.001
|
|
During exposure to MTX without a bDMARDs and with or without other csDMARDs, %
|
|
Any immunosuppressive DMARD use
|
12.7
|
10.9
|
10.2
|
< 0.001
|
|
Taclolimus
|
10.7
|
9.4
|
8.3
|
< 0.001
|
|
Mizoribine
|
1.8
|
1.6
|
2.0
|
0.354
|
|
Leflunomide
|
0.7
|
0.3
|
0.3
|
0.001
|
|
Oral CS use, %
|
51.8
|
55.4
|
63.2
|
< 0.001
|
|
Maximum dose of oral CS c≥ 10 mg/day, %
|
22.2
|
20.1
|
22.2
|
0.016
|
|
Mean dose of oral CS c≥ 10 mg/day, %
|
12.5
|
9.9
|
12.0
|
< 0.001
|
|
Mean dose of oral CS c≥ 7.5 mg/day, %
|
16.0
|
13.4
|
16.7
|
< 0.001
|
